Eliem Therapeutics EBITDA 2021-2024 | CLYM
Eliem Therapeutics ebitda from 2021 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Eliem Therapeutics Annual EBITDA (Millions of US $) |
2023 |
$-43 |
2022 |
$-45 |
2021 |
$-35 |
2020 |
$-21 |
Eliem Therapeutics Quarterly EBITDA (Millions of US $) |
2024-06-30 |
$-56 |
2024-03-31 |
$-3 |
2023-12-31 |
$-5 |
2023-09-30 |
$-6 |
2023-06-30 |
$-7 |
2023-03-31 |
$-24 |
2022-12-31 |
$-10 |
2022-09-30 |
$-9 |
2022-06-30 |
$-14 |
2022-03-31 |
$-13 |
2021-12-31 |
$-10 |
2021-09-30 |
$-9 |
2021-06-30 |
$-9 |
2021-03-31 |
$-7 |
2020-12-31 |
|
2020-09-30 |
$-2 |
2020-06-30 |
$-2 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-DRUGS |
$0.342B |
$0.000B |
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|